A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus

NCT05796206 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: MIL62
DRUG: placebo

Sponsor

Beijing Mabworks Biotech Co., Ltd.